Kellesarian Sergio Varela, Al Amri Mohammad D, Al-Kheraif Abdulaziz A, Ghanem Alexis, Malmstrom Hans, Javed Fawad
Int J Oral Maxillofac Implants. 2017 May/Jun;32(3):497-506. doi: 10.11607/jomi.4955.
In indexed literature, a systematic review of the efficacy of statins in enhancing osseointegration is lacking. The aim of this systematic review was to assess the efficacy of local and systemic statin delivery on the osseointegration of implants.
To address the focused question, "Does local and systemic statin delivery affect osseointegration around implants?", indexed databases were searched from 1965 through November 2015 using various keywords. Letters to the Editor, case reports/case series, historic reviews, and commentaries were excluded. The pattern of this systematic review was customized to primarily summarize the pertinent data.
Nineteen studies were included. All studies were experimental and were performed in animal models. In seven studies, statins were delivered systemically via oral, intraperitoneal, intraosseous, subcutaneous, and percutaneous routes. Among the 12 studies, where statins were delivered locally, statin-coated implants were used in seven studies, whereas in the remaining studies, statins were delivered via topical application on the bone cavities. The follow-up duration ranged between 1 and 12 weeks. Results from 18 studies showed that statin administration enhanced new bone formation (NBF) around implants and/or bone-to-implant contact. One study showed that statin-coated implant surfaces impaired osseointegration. Seven studies reported that statin administration enhanced NBF around implants in osteoporotic rats.
On experimental grounds, local and systemic statin delivery seems to enhance osseointegration; however, from a clinical perspective, further studies are needed to assess the role of statins in promoting osseointegration around dental implants.
在索引文献中，缺乏关于他汀类药物增强骨整合疗效的系统评价。本系统评价的目的是评估局部和全身应用他汀类药物对种植体骨整合的疗效。
为解决核心问题“局部和全身应用他汀类药物是否会影响种植体周围的骨整合？”，使用各种关键词检索了1965年至2015年11月的索引数据库。排除了致编辑信、病例报告/病例系列、历史综述和评论。本系统评价的模式经过定制，主要用于总结相关数据。
纳入19项研究。所有研究均为实验性研究，在动物模型中进行。7项研究中，他汀类药物通过口服、腹腔内、骨内、皮下和经皮途径全身给药。在12项局部应用他汀类药物的研究中，7项研究使用了涂有他汀类药物的种植体，而在其余研究中，他汀类药物通过局部应用于骨腔给药。随访时间为1至12周。18项研究结果表明，给予他汀类药物可增强种植体周围的新骨形成（NBF）和/或骨与种植体的接触。1项研究表明，涂有他汀类药物的种植体表面会损害骨整合。7项研究报告称，给予他汀类药物可增强骨质疏松大鼠种植体周围的NBF。
基于实验结果，局部和全身应用他汀类药物似乎可增强骨整合；然而，从临床角度来看，需要进一步研究来评估他汀类药物在促进牙种植体周围骨整合中的作用。
